Active Recombinant Human Procathepsin K

• Cat.No.: CTSK-680H
• Product Overview: Recombinant human procathepsin K of amino acids Glu19 - Met215 is expressed in E. coli with an additional M-residue at the N-terminus.

Specification

• Cat. No.: CTSK-680H
• Description: The protein encoded by this gene is a lysosomal cysteine proteinase involved in bone remodeling and resorption. This protein, which is a member of the peptidase C1 protein family, is predominantly expressed in osteoclasts. However, the encoded protein is also expressed in a significant fraction of human breast cancers, where it could contribute to tumor invasiveness. Mutations in this gene are the cause of pycnodysostosis, an autosomal recessive disease characterized by osteosclerosis and short stature. This gene may be subject to RNA editing.
• Source: E. coli
• Molecular Mass: Active cathepsin obtained after removal of the propeptide has a molecular weight of about 24 kDa.
• Form: The proenzyme is dissolved in 500 mM NaCl, 25 mM TrisHCl, pH 8.0.
• Purity: Recombinant procathepsin K appears as a major protein band of about 35 kDa in SDS-PAGE (> 95 % of total protein) and Western Blotting.
• Specific activity: The specific activity of activated cathepsin K is > 1 U/mg. One U is the activity that hydrolyses 1 µmole substrate BOC-Phe-Arg-7-amido-4-methylcoumarin per min at 37oC in 2.5 mM EDTA, 5 mM DTT, 50 mM MES, pH 5.5.
• Inhibitors: Cathepsin K is inhibited by leupeptin (IC50: 70 nM), E-64 (IC50: 5 nM), and cystatin.
• Stability andstorage: Procathepsin K is stable until the expiry date given on the label if stored at -80°C. Repeated freezing and thawing must be avoided. After activation the enzyme is rather unstable. If the activated enzyme is not used immediately, it is recommended to add MMTS (1 mM final concentration). For activity measurements L-cysteine must then be added to restore the active conformation of the enzyme.
• Applications: Characterization of cathepsin K structure and function; Screening of inhibitors for cathepsin K; Drug target for diseases characterized by excessive bone reabsorption, such as osteoporosis.
• OfficialSymbol: CTSK
• Tag: Non
• Protein length: Glu19-Met215

Gene Information

• Gene Name: CTSK cathepsin K [ Homo sapiens ]
• Synonyms: CTSK; cathepsin K; CTSO; PKND; PYCD; CTS02; CTSO1; CTSO2; MGC23107; cathepsin K; cathepsin X; cathepsin O1; cathepsin O2; EC 3.4.22.38; cathepsin K (pycnodysostosis); OTTHUMP00000032938; Cathepsin O
• Gene ID: 1513
• mRNA Refseq: NM_000396
• Protein Refseq: NP_000387
• MIM: 601105
• UniProt ID: P43235
• Chromosome Location: 1q21
• Pathway: Lysosome; Activation of Matrix Metalloproteinases; Adaptive Immune System
• Function: cysteine-type endopeptidase activity; cysteine-type peptidase activity

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.